Qiagen gets a DZ Bank lift, analyst consensus shapes the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 13:18.

Qiagen N.V. (NL0015002SN0) draws fresh attention from Frankfurt on Tuesday. DZ Bank lifts its fair value estimate to 40 euros and reiterates a Buy rating in a sector study that highlights artificial intelligence tailwinds for life science suppliers. DZ Bank analysis flash

What DZ Bank now says

DZ Bank’s study, published on Tuesday morning, raises the fair value for Qiagen from 38 euros to 40 euros and keeps the recommendation at Buy, underscoring a constructive stance despite recent share price weakness. dpa-AFX broker note on Qiagen Analyst Sven Kürten describes artificial intelligence as "more friend than foe" for the life-science supplier segment, pointing to efficiency gains and new diagnostics applications.

Within that framework, Qiagen is characterized as one of the most multifaceted names in the peer group, with a mix of sizeable opportunities and specific risks in integrating AI into its workflows and product development. Sector study excerpt DZ Bank sees an expected business recovery in the second half of 2026 as a key near-term driver, a point that aligns with the broader narrative of normalization after pandemic-era demand distortions.

How the analyst consensus looks

Beyond DZ Bank, the broader sell-side picture remains constructive but mixed. MarketBeat data shows a consensus Hold rating for Qiagen based on 12 analysts, with 5 Buys, 6 Holds and 1 Sell; the average price target sits around 36 to 44 dollars per share, implying mid-teens percentage upside from recent trading on the NYSE. MarketBeat analyst forecast for Qiagen This distribution reflects balanced expectations, with some houses cautious on near-term growth and others focused on margin resilience.

German retail platforms also signal notable upside: wallstreet-online aggregates seven analyst targets with an average of about 50.14 euros, which stands more than 50 percent above recent Xetra levels around 32.5 euros. wallstreet-online Qiagen analyst overview The lowest target in that sample is 46 euros and the highest 59 euros, underlining that most coverage still assumes a meaningful re-rating if Qiagen delivers the expected second-half improvement.

The product behind the stock

Qiagen generates its revenue as a life-science and molecular diagnostics supplier, with sample preparation kits and consumables as a core pillar. A representative product line is its QIAamp nucleic acid purification kits, widely used in laboratories to extract DNA and RNA from clinical and research samples for downstream analysis and sequencing. Qiagen product and business overview

Where the shares trade today

The Qiagen shares (NL0015002SN0) trade on Xetra at 32.41 euros as of 2026-06-23, 09:20, while the QGEN listing on the NYSE recently closed at 36.42 dollars on 2026-06-22. Realtime Xetra quote for Qiagen

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. All data are based on sources cited in the text and may change over time.